Your browser doesn't support javascript.
loading
Characteristics and risk factors of interstitial pneumonia with autoimmune features.
Vahidy, Sana; Agyeman, Jonathan; Zheng, Boyang; Donohoe, Kathryn; Hambly, Nathan; Johannson, Kerri A; Assayag, Deborah; Fisher, Jolene H; Manganas, Helene; Marcoux, Veronica; Khalil, Nasreen; Kolb, Martin; Ryerson, Christopher J; Wong, Alyson W; Lok, Stacey; Morisset, Julie; Fell, Charlene D; Shapera, Shane; Gershon, Andrea S; Cox, Gerard; Halayko, Andrew J; Sadatsafavi, Mohsen; Wilcox, Pearce G; To, Teresa.
Afiliação
  • Vahidy S; Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.
  • Agyeman J; Department of Statistics, University of British Columbia, Vancouver, BC, Canada.
  • Zheng B; Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Division of Rheumatology, McGill University, Montreal, QC, Canada.
  • Donohoe K; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Hambly N; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Johannson KA; Department of Medicine, University of Calgary, Calgary, AB, Canada.
  • Assayag D; Department of Medicine, McGill University, Montreal, QC, Canada.
  • Fisher JH; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Manganas H; Department of Medicine, Université de Montréal, Montreal, QC, Canada.
  • Marcoux V; Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
  • Khalil N; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Kolb M; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Ryerson CJ; Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada. Electronic address: chris.ryerson@hli.ubc.ca.
  • Wong AW; Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.
  • Lok S; Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
  • Morisset J; Department of Medicine, Université de Montréal, Montreal, QC, Canada.
  • Fell CD; Department of Medicine, University of Calgary, Calgary, AB, Canada.
  • Shapera S; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Gershon AS; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Cox G; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Halayko AJ; Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.
  • Sadatsafavi M; Phamaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
  • Wilcox PG; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • To T; Department of Medicine, University of Toronto, Toronto, ON, Canada.
Respir Med ; 221: 107500, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38142756
ABSTRACT

BACKGROUND:

Interstitial pneumonia with autoimmune features (IPAF) has features of connective tissue disease-associated interstitial lung disease (CTD-ILD), but without meeting criteria for a specific CTD. We compared baseline characteristics, survival, and response to treatment of IPAF to both CTD-ILD and unclassifiable ILD.

METHODS:

Measurements were extracted from a prospective registry. Baseline features and survival were compared in IPAF against both CTD-ILD and unclassifiable ILD. Linear trajectory of lung function decline (%-predicted forced vital capacity [FVC%] and diffusion capacity of the lung for carbon monoxide [DLCO%]) before and after initiation of mycophenolate or azathioprine were compared in IPAF against both CTD-ILD and unclassifiable ILD using linear mixed models.

RESULTS:

Compared to CTD-ILD (n = 1240), patients with IPAF (n = 128) were older, more frequently male, and had greater smoking history. Compared to unclassifiable ILD (n = 665), patients with IPAF were younger, more frequently female, and had worse baseline lung function. IPAF had higher mortality compared to CTD-ILD and similar risk of mortality compared to unclassifiable ILD. Mycophenolate initiation was associated with stabilization of FVC% and DLCO% in all ILD subtypes except for FVC% in patients with IPAF, and azathioprine initiation with stabilization of FVC% and DLCO% in all ILD subtypes except for FVC% decline in IPAF and DLCO% decline in CTD-ILD.

CONCLUSION:

Patients with IPAF had worse survival compared to those with CTD-ILD and similar mortality to unclassifiable ILD, with treatment being associated with stabilization in lung function in all three ILDs. It is uncertain whether IPAF should be considered a distinct ILD diagnostic subgroup.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 4_TD / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Doenças do Tecido Conjuntivo Limite: Female / Humans / Male Idioma: En Revista: Respir Med Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 4_TD / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Doenças do Tecido Conjuntivo Limite: Female / Humans / Male Idioma: En Revista: Respir Med Ano de publicação: 2024 Tipo de documento: Article